BACKGROUND: @entity0 becomes lethal when visceral metastases develop. At this stage, anti- @entity5 treatments aim at relieving symptoms and delaying @entity204 without resulting in additional @entity137 . On the basis of their differential anti-oxidant defence level, @entity5 cells can be made more sensitive to chemotherapy than non- @entity5 cells when membrane lipids are enriched with @entity4600 ( @entity4601 ), a peroxidisable and oxidative-stress-inducing lipid of marine origin. METHODS: This open-label single-arm phase II study evaluated the safety and efficacy (response rate), as primary end points, of the addition of 1.8 g @entity4601 daily to an @entity4349 -based chemotherapy (FEC) regimen in @entity0 @entity1 (n = 25) with rapidly progressing visceral metastases. The secondary end points were @entity1054 ( @entity1054 ) and @entity1349 ( @entity1349 ). RESULTS: The objective response rate was 44%. With a mean follow-up time of 31 months (range 2-96 months), the median @entity1054 was 6 months. Median @entity1349 was 22 months and reached 34 months in the sub-population of @entity1 (n = 12) with the highest plasma @entity4601 incorporation. The most common grade 3 or 4 @entity137 was neutropaenia (80%). CONCLUSION: @entity4601 during chemotherapy was devoid of adverse side effects and can improve the outcome of chemotherapy when highly incorporated. @entity4601 has a potential to specifically chemosensitise @entity5 .

Improving outcome of chemotherapy of metastatic @entity0 by XXXX : a phase II trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer'] @entity4600 :: ('CHEBI:28125', 'Chemical') :: ['docosahexaenoic acid'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumours', 'tumour'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity4601 :: ('CHEBI:16016', 'Chemical') :: ['DHA'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity4600 :: (CHEBI:28125,Chemical) :: ['docosahexaenoic acid']
